Guardant Health, Inc.

GH Healthcare Diagnostics & Research

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue
+36.1%
EPS
−25.7%
Free cash flow
+18.7%
Total debt
+34.8%

Quarter to September 2026, against a year earlier

150.01 3.42 −2.23%
Market cap
$20.6B
P/E
0.0×
Fwd P/E
−55.6×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.78
Dividend safety
n/a

Guardant Health, Inc. 10-Q filed May 7, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 5:16 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov